Remove Biopharma Remove Competition Remove Healthcare Remove Sales
article thumbnail

Navigating the Challenges of Biopharma Product Launches: A Blueprint for Success

PM360

Embarking on the journey from product development to market success in the biopharma industry is no small feat. The landscape is highly competitive with new prescription medications launching worldwide each year. However, this journey is fraught with challenges as revealed by an in-depth analysis.

article thumbnail

Biogen Bows Out of Acorda Pact on MS Med; Focus Turns to New Growth Drivers

MedCity News

Generic competition has eroded sales of multiple sclerosis drug Ampyra, marketed as Fampyra outside the U.S. Biogen told Acorda Therapeutics that it’s terminating its ex-U.S. rights to Fampyra in order to focus on other priorities, which include expanding beyond MS.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

When Simple Isn’t Simple: Why Your Sales Compensation Plan is Not as Simple as You Think

The Marketing Advantage

September 8, 2021 Over the years, the healthcare industry has progressively grown more and more complex, from the increasing influence of managed care companies to intensifying governmental regulations to new data sources. In parallel with this growing industry-wide complexity has been the call to further simplify sales compensation plans.

Sales 52
article thumbnail

Achieving commercial excellence with data-driven decisions

pharmaphorum

Together, these groups compile vast amounts of data, including rich information on patient populations, target customers, and the competitive landscape. How can we maximise marketing, sales, medical, access, and other teams’ efforts while making their jobs easier? Truly understanding the competitive landscape and market environment.

article thumbnail

HCP Engagement & Education

PM360

In this issue, we take a closer look on the importance of patient education to Healthcare Professionals and navigating the challenges that arise. With an ever- increasing demand for their time and attention, it is more difficult than ever for biopharma representatives to convey their message to the physician audience.

article thumbnail

Genentech’s Chief Marketing Officer Talks Marketing’s New Role and Data-Driven Content

PM360

I recently sat down with Erica Taylor, PhD, Vice President and Chief Marketing Officer at Genentech, to talk about the future of biopharma marketing and creating more meaningful content. Pooja Ojala: How do you approach marketing to adapt to today’s healthcare landscape?

Marketing 105
article thumbnail

Five points on CMS’s first ten picks for price negotiations

Clarivate

exclusions exist for orphan drug designation and biosimilar competition ). Under buy and bill (B&B) in Medicare Part B, physician practices profit from reimbursement (historically Average Sales Price + 6% before sequestration) as well as rebates and discounts negotiated with manufacturers for hitting volume levels.